Huang Ching-Ya, You Ying-Shu, Lai Jian-Ming, Lin Cheng-Li, Hsu Hsing-Yu, Hsieh Yow-Wen
Department of Pharmacy, Asia University Hospital, Taichung, Taiwan.
School of Pharmacy, China Medical University, Taichung, Taiwan.
Drugs Real World Outcomes. 2024 Sep;11(3):513-520. doi: 10.1007/s40801-024-00419-0. Epub 2024 Jun 5.
The complex risk factors of liver injury have prevented the establishment of causal relationships. This study aimed to explore the effects of antidepressant class, cumulative days of medication exposure, presence of comorbidities, and the use of confounding drugs on the risk of antidepressant-induced liver injury.
The population-based case-control study sample included individuals registered on the Taiwan National Health Insurance Database between 2000 and 2018. Hospitalized patients with suspected drug-induced liver injury were considered as cases, while control subjects were matched 1:1 by age, gender, and index date (the first observed diagnosis of liver injury). Multivariable regression models were performed to evaluate the association between antidepressants and liver injury.
The findings showed that antidepressant users exhibited a higher risk of liver injury (adjusted odds ratio [aOR] 1.16, 95% confidence interval [CI] 1.12-1.20), particularly those prescribed non-selective serotonin reuptake inhibitors (NSRIs; aOR 1.05; 95% CI 1.01-1.10), selective serotonin reuptake inhibitors (SSRIs; aOR 1.22; 95% CI 1.16-1.29), serotonin-norepinephrine reuptake inhibitors (SNRIs; aOR 1.18; 95% CI 1.13-1.24), and others (aOR 1.27; 95% CI 1.14-1.42). Moreover, cases exhibited a more significant proportion of antidepressant usage and longer durations of treatment compared with controls. The risk of liver injury was higher in the first 30 days of use across all classes of antidepressants (aOR 1.24; 95% CI 1.18-1.29).
SSRIs or SNRIs are commonly used to treat depression and other psychological disorders, and consideration of their potential effects on the liver is essential.
肝损伤的复杂风险因素阻碍了因果关系的确立。本研究旨在探讨抗抑郁药类别、药物暴露累积天数、合并症的存在以及混杂药物的使用对抗抑郁药所致肝损伤风险的影响。
基于人群的病例对照研究样本包括2000年至2018年在台湾国民健康保险数据库登记的个体。疑似药物性肝损伤的住院患者被视为病例,而对照对象按年龄、性别和索引日期(首次观察到的肝损伤诊断)进行1:1匹配。采用多变量回归模型评估抗抑郁药与肝损伤之间的关联。
研究结果表明,抗抑郁药使用者肝损伤风险更高(调整优势比[aOR]为1.16,95%置信区间[CI]为1.12 - 1.20),尤其是那些被开具非选择性5-羟色胺再摄取抑制剂(NSRIs;aOR为1.05;95% CI为1.01 - 1.10)、选择性5-羟色胺再摄取抑制剂(SSRIs;aOR为1.22;95% CI为1.16 - 1.29)、5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRIs;aOR为1.18;95% CI为1.13 - 1.24)以及其他药物(aOR为1.27;95% CI为1.14 - 1.42)的患者。此外,与对照组相比,病例组抗抑郁药使用比例更高且治疗持续时间更长。所有类别抗抑郁药在使用的前30天内肝损伤风险更高(aOR为1.24;95% CI为1.18 - 1.29)。
SSRI或SNRI常用于治疗抑郁症和其他心理障碍,考虑它们对肝脏的潜在影响至关重要。